Since November 2016, the German state North Rhine-Westphalia financial support the I³-STM project for the development of synthetic antibodies (SAB) as unique individualized immuno-oncological approach for improved breast cancer treatment of triple negative breast cancer (TNBC). SABs recognize tumor-specific marker molecules on the tumor endothelium and in the stroma. Gremse-IT GmbH is a part of the consortium as a SME. In this project, Gremse-IT performed µCT-FMT-reconstruction for the cooperation partners, and provided the analysis software to assess the distribution of fluorescence  intensities in single organs of interest as well as in the tumor.